Hwang Se Hwan, Lee Ho Seok, Joo Young Hoon, Seo Jae Hyun, Kang Jun Myung
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Laryngoscope. 2018 Mar;128(3):573-580. doi: 10.1002/lary.26787. Epub 2017 Sep 25.
The goal of this meta-analysis was to perform a systematic review of the literature on the effect of dexmedetomidine on perioperative morbidity following nasal surgery and on the adverse effects of dexmedetomidine.
MEDLINE, Scopus, and Cochrane Database of Systematic Reviews.
Two authors independently searched scientific and medical databases from their inception of article collection to March 2017. Studies that compared perioperative dexmedetomidine administration (dexmedetomidine group) with another agent under monitored anesthesia care (MAC) or general anesthesia (control group) with outcomes of interest that were perioperative pain intensity; rescue analgesic consumption; or adverse effects such as hemodynamic instability, nausea, and vomiting (PONV), and operative bleeding were included in the analysis.
Perioperative pain scores and postoperative need for analgesics were significantly decreased in the dexmedetomidine group versus control group (other agent or general anesthesia). In subgroup analysis according to anesthesia type (general anesthesia and other sedatives in MAC), dexmedetomidine showed a similar effect on bradycardia, hypotension, and desaturation with general anesthesia, but it reduced PONV effectively compared with general anesthesia. Additionally, dexmedetomidine satisfied patient significantly. By contrast, compared with other sedative under MAC, it provoked bradycardia significantly.
This meta-analysis showed that systemic administration of dexmedetomidine efficiently can decrease intraoperative and postoperative pain without adverse effects such as nausea, vomiting, and respiratory depression. Dexmedetomidine also can decrease analgesic consumption. However, clinicians should be aware of the potential for intraoperative bradycardia; patients also should be educated regarding these possibilities.
NA. Laryngoscope, 128:573-580, 2018.
本荟萃分析的目的是对右美托咪定对鼻科手术后围手术期发病率的影响以及右美托咪定的不良反应相关文献进行系统评价。
医学文献数据库(MEDLINE)、Scopus数据库以及Cochrane系统评价数据库。
两位作者独立检索了从文章收录起始至2017年3月的科学和医学数据库。比较围手术期给予右美托咪定(右美托咪定组)与在监护麻醉(MAC)或全身麻醉下使用另一种药物(对照组),观察感兴趣的结局,包括围手术期疼痛强度、补救性镇痛药用量,或诸如血流动力学不稳定、恶心和呕吐(术后恶心呕吐)以及手术出血等不良反应的研究纳入分析。
与对照组(其他药物或全身麻醉)相比,右美托咪定组围手术期疼痛评分及术后镇痛药需求显著降低。在根据麻醉类型(全身麻醉和MAC中的其他镇静剂)进行的亚组分析中,右美托咪定在全身麻醉时对心动过缓、低血压和血氧饱和度降低显示出类似的影响,但与全身麻醉相比,它能有效降低术后恶心呕吐。此外,右美托咪定显著提高了患者满意度。相比之下,与MAC下的其他镇静剂相比,它显著引发心动过缓。
本荟萃分析表明,全身给予右美托咪定可有效降低术中和术后疼痛,且无恶心、呕吐和呼吸抑制等不良反应。右美托咪定还可减少镇痛药用量。然而,临床医生应意识到术中发生心动过缓的可能性;也应告知患者这些可能性。
无。《喉镜》,2018年,第128卷,第573 - 580页